Placebo-Controlled Evaluation of Ritalin Side Effects
1 From the Department of Neurology, Marshfield Medical Research Foundation, Marshfield, WI.
2 From the Department of Neuropsychology, Marshfield Medical Research Foundation, Marshfield, WI.
3 From the Department of Epidemiology and Biostatistics, Marshfield Medical Research Foundation, Marshfield, WI.
4 From the Department of Pediatrics, Marshfield Clinic, Marshfield Medical Research Foundation, Marshfield, WI.
Objective. To address the frequency of side effects of Ritalin therapy in children with attention deficit hyperactivity disorder (ADHD) using the Barkley Side Effects Questionnaire (BSEQ) in a clinical setting.
Design. Randomized double-blind placebo-controlled cross-over trial.
Setting. A large rural tertiary care clinic.
Patients. 234 consecutive children aged 5 through 15 years who met the Diagnostic and Statistical Manual of Mental Disorders (3rd ed, revised) criteria for ADHD were enrolled. Of these children, 206 had sufficient side effects data for analysis.
Interventions. 0.3 mg/kg per dose and 0.5 mg/kg per dose Ritalin compared to placebo in separate 2-week trials. Each treatment was given three times a day for 7 consecutive days.
Measurements and main results. Parents, blinded to the treatment assignment, assessed side effects via the BSEQ at baseline and at the end of each of the 4 treatment weeks. Univariate odds ratios (OR) were used to describe the magnitude of differences in observed side effects between Ritalin and placebo weeks of the trial for each of the items on the BSEQ. The frequency of the following side effects significantly increased with Ritalin therapy: insomnia (OR = 3.13, 95% confidence interval [CI] = (1.80,5.42)), appetite disturbance (OR = 19.00, 95% CI = (9.18,39.31)), stomachache (OR = 7.00, 95% CI = (3.29, 14.89)), headache (OR = 5.29, 95% CI = (2.51,11.15)), and dizziness (OR = 7.50, 95% CI = (1.93,29.13)). The frequency of the following side effects significantly decreased with Ritalin therapy: staring and daydreaming (OR = 0.47, 95% CI = (0.27,0.84)), irritability (OR = 0.33, 95% CI = (0.18,0.61)), anxiety (OR = 0.42, 95% CI = (0.23,0.76)), and nailbiting (OR = 0.19, 95% CI = (0.07, 0.53)). The incidence rates of the remaining BSEQ items did not differ significantly between the Ritalin and placebo weeks of the trial.
Conclusion. The BSEQ proved to be clinically effective in tracking Ritalin side effects and should be incorporated into the routine evaluation and monitoring of ADHD patients for whom stimulants are prescribed.
Key Words: attention deficit hyperactivity disorder • side effects • Ritalin
Submitted on November 13, 1991
Accepted on December 31, 1992
CiteULike 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  H. M. Conklin, J. Lawford, B. W. Jasper, E. B. Morris, S. C. Howard, S. W. Ogg, S. Wu, X. Xiong, and R. B. Khan Side Effects of Methylphenidate in Childhood Cancer Survivors: A Randomized Placebo-Controlled Trial Pediatrics, July 1, 2009; 124(1): 226 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. van der Heijden, M. G. Smits, and W. B. Gunning Sleep-related Disorders in ADHD: A Review Clinical Pediatrics, April 1, 2005; 44(3): 201 - 210. [PDF]
|
|
|
|
|
|
M. A. Stein, C. S. Sarampote, I. D. Waldman, A. S. Robb, C. Conlon, P. L. Pearl, D. O. Black, K. E. Seymour, and J. H. Newcorn A Dose-Response Study of OROS Methylphenidate in Children With Attention-Deficit/Hyperactivity Disorder Pediatrics, November 1, 2003; 112(5): e404 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Kuperman, I. Yaniv, B. Stahl, and H. Tamary Methylphenidate as a possible cause of thrombocytopenia Ann. Pharmacother., July 1, 2003; 37(7): 1146 - 1146. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Stein, R. Pat-Horenczyk, S. Blank, Y. Dagan, Y. Barak, and T. P. Gumpel Sleep Disturbances in Adolescents with Symptoms of Attention-Deficit/Hyperactivity Disorder J Learn Disabil, May 1, 2002; 35(3): 268 - 275. [Abstract] [PDF]
|
|
|
|
 |
|
 M.D. Rapport, R. Randall, and C. Moffitt Attention-Deficit/Hyperactivity Disorder and Methylphenidate: A dose-response analysis and parent-child comparison of somatic complaints J Atten Disord, January 1, 2002; 6(1): 15 - 24. [Abstract] [PDF]
|
|
|
|
|
|
M. L. Wolraich, L. L. Greenhill, W. Pelham, J. Swanson, T. Wilens, D. Palumbo, M. Atkins, K. McBurnett, O. Bukstein, G. August, et al. Randomized, Controlled Trial of OROS Methylphenidate Once a Day in Children With Attention-Deficit/Hyperactivity Disorder Pediatrics, October 1, 2001; 108(4): 883 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Ahmann, F. W. Theye, R. Berg, A. J. Linquist, A. J. Van Erem, and L. R. Campbell Placebo-Controlled Evaluation of Amphetamine Mixture{---}Dextroamphetamine Salts and Amphetamine Salts (Adderall): Efficacy Rate and Side Effects Pediatrics, January 1, 2001; 107(1): 10e - 10. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. R. White and C. M. Yadao Characterization of Methylphenidate Exposures Reported to a Regional Poison Control Center Arch Pediatr Adolesc Med, December 1, 2000; 154(12): 1199 - 1203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Zito, D. J. Safer, S. dosReis, J. F. Gardner, M. Boles, and F. Lynch Trends in the Prescribing of Psychotropic Medications to Preschoolers JAMA, February 23, 2000; 283(8): 1025 - 1030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R Burgess, L. Stevens, W. Zhang, and L. Peck Long-chain polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder Am. J. Clinical Nutrition, January 1, 2000; 71(1): 327S - 330S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Kent, C. S. Camfield, and P. R. Camfield Double-blind Methylphenidate Trials: Practical, Useful, and Highly Endorsed by Families Arch Pediatr Adolesc Med, December 1, 1999; 153(12): 1292 - 1296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ring, D. Stein, Y. Barak, A. Teicher, J. Hadjez, A. Elizur, and A. Weizman Sleep Disturbances in Children with Attention-Deficit/Hyperactivity Disorder: A Comparative Study with Healthy Siblings J Learn Disabil, November 1, 1998; 31(6): 572 - 578. [Abstract] [PDF]
|
|
|
|
|
|
L. S. Goldman, M. Genel, R. J. Bezman, P. J. Slanetz, and for the Council on Scientific Affairs, American Me Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents JAMA, April 8, 1998; 279(14): 1100 - 1107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Efron, F. Jarman, and M. Barker Side Effects of Methylphenidate and Dexamphetamine in Children With Attention Deficit Hyperactivity Disorder: A Double-blind, Crossover Trial Pediatrics, October 1, 1997; 100(4): 662 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. G. Scbulz and M. C. Edwards Stimulant Medication Management of Students with Attention Deficit Hyperactivity Disorder: What Educators Need to Know Teacher Education and Special Education: The Journal of the Teacher Education Division of the Council for Exceptional Children, April 1, 1997; 20(2): 170 - 178. [Abstract] [PDF]
|
|
|
|
 |
|
 D. C. Vinson Therapy for Attention-Deficit Hyperactivity Disorder Arch Fam Med, May 1, 1994; 3(5): 445 - 451. [Abstract] [PDF]
|
|
